PharmiWeb.com - Global Pharma News & Resources
26-Dec-2018

Global Glioma Therapeutics Market 2019-2023| Special Regulatory Designations to Boost Growth| Technavio

Technavio analysts forecast the global glioma therapeutics market to grow at a CAGR of over 9% during the forecast period, according to their latest market research report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181226005055/en/

Technavio has published a new market research report on the global glioma therapeutics market from 2019-2023. (Graphic: Business Wire)

Development of biosimilars for the treatment of glioma is one of the major trends being witnessed in the global glioma therapeutics market 2019-2023. Currently, Bevacizumab is the only approved biologic for the treatment of glioma. However, the recent expiration of some of its exclusive rights is providing immense opportunities for vendors to enter the market with new drugs for the treatment of glioma. Therefore, several pharmaceutical companies are focusing on the development of bevacizumab biosimilars. Thus, the development of low-cost therapeutics will boost the growth of global glioma therapeutics market during the forecast period.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Global glioma therapeutics market: Special regulatory designations

The prevalence rate of glioma is usually lower than other mainstream diseases such as diabetes and hypertension, as it is a rare disorder. Consequently, pharmaceutical companies are often hesitant to invest a significant amount in R&D for drug discovery. Therefore, regulatory bodies provide special drug designations such as fast-track designation, orphan drug designation, and Qualified Infectious Disease Product (a DP) designations.

The orphan drug designation will propel the growth of the global glioma therapeutics market, as it will support and incentivize pharmaceutical companies to engage in the development of therapeutics pipeline for the treatment of glioma.

According to a senior analyst at Technavio, “Apart from the development of biosimilars for the treatment of glioma, factors such as the strategic alliances, and the development of gene therapy for the treatment are expected to positively impact the growth of the global glioma therapeutics market during the forecast period.”

Global glioma therapeutics market: Segmentation analysis

The global glioma therapeutics market research report provides market segmentation by product (small molecules, and biologics), and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

The Americas region held the largest share of the market in 2018, accounting for over 41% share, followed by EMEA and APAC respectively. Although the APAC region held the smallest share of the market in 2018, it is expected to register the highest incremental growth during the forecast period.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181226005055/en/

Editor Details

Last Updated: 26-Dec-2018